Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-034634
Filing Date
2025-03-06
Accepted
2025-03-06 16:10:30
Documents
1
Period of Report
2025-03-04

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 7123
  Complete submission text file 0000950170-25-034634.txt   8586
Mailing Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017
Business Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017 781-419-1400
Syndax Pharmaceuticals Inc (Issuer) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O SYNDAX PHARMACEUTICALS, INC. 400 TOTTEN POND ROAD, WALTHAM MA 02451
Business Address
Metzger Michael A (Reporting) CIK: 0001507220 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37708 | Film No.: 25715309